torcetrapib


Also found in: Wikipedia.

torcetrapib

A cholesterol ester transfer protein (CETP) inhibitor drug that has been shown capable of substantially increasing levels of high density lipoprotein (HDL) cholesterol. A major trial of this drug in conjunction with atorvastatin was stopped by Pfizer at the end of 2006.
References in periodicals archive ?
In the case of torcetrapib, the first CETP inhibitor tested in a large-scale clinical Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial, the clinical trial was terminated early because of off-target adverse events (increased serum aldosterone and blood pressure levels) (50).
The first CETP inhibitor, torcetrapib, proved unsuccessful because it increased levels of aldosterone, a hormone that increases blood pressure.
Torcetrapib and carotid intima-media thickness in mixed dyslipidaemia (RADIANCE 2 study): A randomised, double-blind trial.
Torcetrapib and atorvastatin - should marketing drive the research agenda?
Pfizer, for example, spent a reported $800 million on its cholesterol-lowering drug, torcetrapib, before pulling it from phase III clinical trials in 2006.
stopped a late-stage study of its CETP inhibitor, torcetrapib, in late 2006, when the drag--despite raising good cholesterol levels as intended--was found to increase the risk of death and heart problems in a clinical trial.
A CETP inhibitor that raises HDL cholesterol while reducing the LDL variety evacetrapib could be a huge seller for Lilly, or it could meet the same fate as Pfizer's torcetrapib and Roche's dalcetrapib.
Like dalcetrapib, torcetrapib raised HDL-cholesterol levels in patients who were at high risk for cardiovascular disease.
But clinical trials were stopped in 2006, when an excess number of deaths occurred in clinical trial participants taking torcetrapib.
For example, making the liver produce more HDL might be better than drugs like dalcetrapib and torcetrapib, which keep cholesterol in HDL," he explains.
The first drug in the class, torcetrapib, failed due to unexpected toxicity, but many researchers believe that newer compounds such as evacetrapib may avoid this toxicity.
It is still early days for dalcetrapib, and medical experts remain wary following the high-profile failure of a similar drug from Pfizer called torcetrapib.